DK1005332T3 - Farmaceutisk præparat til reduktion af produktion af MCP-1-protein - Google Patents

Farmaceutisk præparat til reduktion af produktion af MCP-1-protein

Info

Publication number
DK1005332T3
DK1005332T3 DK98943862T DK98943862T DK1005332T3 DK 1005332 T3 DK1005332 T3 DK 1005332T3 DK 98943862 T DK98943862 T DK 98943862T DK 98943862 T DK98943862 T DK 98943862T DK 1005332 T3 DK1005332 T3 DK 1005332T3
Authority
DK
Denmark
Prior art keywords
mcp
protein
pharmaceutical composition
reducing production
reducing
Prior art date
Application number
DK98943862T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Alberto Mantovani
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of DK1005332T3 publication Critical patent/DK1005332T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98943862T 1997-07-28 1998-07-22 Farmaceutisk præparat til reduktion af produktion af MCP-1-protein DK1005332T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004924 WO1999004770A2 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Publications (1)

Publication Number Publication Date
DK1005332T3 true DK1005332T3 (da) 2004-02-09

Family

ID=11377642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98943862T DK1005332T3 (da) 1997-07-28 1998-07-22 Farmaceutisk præparat til reduktion af produktion af MCP-1-protein

Country Status (16)

Country Link
US (1) US6534534B1 (da)
EP (1) EP1005332B1 (da)
JP (2) JP4651191B2 (da)
AR (1) AR016382A1 (da)
AT (1) ATE251902T1 (da)
AU (1) AU744492B2 (da)
CA (1) CA2300289C (da)
DE (1) DE69819012T2 (da)
DK (1) DK1005332T3 (da)
ES (1) ES2207858T3 (da)
HK (1) HK1028561A1 (da)
IT (1) IT1293795B1 (da)
PT (1) PT1005332E (da)
SI (1) SI1005332T1 (da)
WO (1) WO1999004770A2 (da)
ZA (1) ZA986636B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
US7919518B2 (en) * 2008-03-07 2011-04-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
EP2262777B8 (en) * 2008-03-07 2016-05-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
BRPI0907974A2 (pt) 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
JP5640086B2 (ja) 2009-08-03 2014-12-10 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ １−ベンジル−３−ヒドロキシメチル−１ｈ−インダゾール及びその誘導体の製造方法並びに必要なマグネシウム中間体
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP2539710A4 (en) 2010-02-25 2016-07-06 Prairie Ventures Llc SYSTEM AND METHOD FOR THE HANDLING, STORAGE AND ANALYSIS OF ANATOMICAL ILLICITATION SAMPLES
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2016277126A1 (en) 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
BR112019011825A2 (pt) 2016-12-12 2019-10-22 Vettore Llc composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
WO1994009128A1 (en) * 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Also Published As

Publication number Publication date
DE69819012T2 (de) 2004-08-12
JP5086322B2 (ja) 2012-11-28
ZA986636B (en) 1999-02-04
PT1005332E (pt) 2004-03-31
JP4651191B2 (ja) 2011-03-16
AR016382A1 (es) 2001-07-04
ATE251902T1 (de) 2003-11-15
HK1028561A1 (en) 2001-02-23
JP2001510793A (ja) 2001-08-07
AU744492B2 (en) 2002-02-28
EP1005332B1 (en) 2003-10-15
WO1999004770A2 (en) 1999-02-04
AU9160198A (en) 1999-02-16
US6534534B1 (en) 2003-03-18
CA2300289C (en) 2007-11-20
EP1005332A2 (en) 2000-06-07
CA2300289A1 (en) 1999-02-04
JP2010047609A (ja) 2010-03-04
ITMI971789A1 (it) 1999-01-28
IT1293795B1 (it) 1999-03-10
DE69819012D1 (de) 2003-11-20
SI1005332T1 (en) 2004-02-29
ES2207858T3 (es) 2004-06-01
WO1999004770A3 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
PT1066027E (pt) Composicao farmaceutica de topiramato
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
ID18663A (id) Komposisi farmasi berlapis enterik
PT981375E (pt) Composicoes farmaceuticas contendo proteinas do plasma
DK1035833T3 (da) Sammensætning til nasal indgivelse
NO20015175L (no) Farmasöytisk sammensetning
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
PT907364E (pt) Composicao farmaceutica de libertacao sustida
ID29262A (id) Komposisi farmasi
ATE260674T1 (de) Stabilisierte proteinzusammensetzung
ID27201A (id) Komposisi farmasi
ID21009A (id) Komposisi untuk supositori
DK1121116T3 (da) Farmaceutisk præparat af fluvastatin med opretholdt frigivelse
DK1005332T3 (da) Farmaceutisk præparat til reduktion af produktion af MCP-1-protein
NO20010089D0 (no) Farmasöytisk levotyroksinpreparat
ID29294A (id) Komposisi farmasi
DE69804218T2 (de) Zementzusammensetzung
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
ID26215A (id) Komposisi farmasi
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
DK0855379T3 (da) Fremgangsmåde til fremstilling af benzophenonderivater
ITMI962628A0 (it) Composizione farmaceutica